✦ LIBER ✦

ABT-431, a D1 receptor agonist prodrug, has efficacy in Parkinson's disease

✍ Scribed by O. Rascol; O. Blin; C. Thalamas; S. Descombes; C. Soubrouillard; P. Azulay; N. Fabre; F. Viallet; K. Lafnitzegger; S. Wright; J. H. Carter; J. G. Nutt

Publisher: John Wiley and Sons
Year: 1999
Tongue: English
Weight: 163 KB
Volume: 45
Category: Article
ISSN: 0364-5134
DOI: 10.1002/1531-8249(199906)45:6<736::aid-ana7>3.0.co;2-f

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

N-0923, a selective dopamine D2 receptor

N-0923, a selective dopamine D2 receptor agonist, is efficacious in rat and monkey models of Parkinson's disease

✍ Dr. J. D. Belluzzi; E. F. Domino; J. M. May; K. S. Bankiewicz; D. A. McAfee 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 800 KB

## Abstract Certain aminotetralins are known to be potent dopamine D~2~ receptor agonists. N‐0923, [‐]2‐(N‐propyl‐N‐2‐thienylethylamino)‐5‐hydroxytetralin HCl, recognizes the high and low affinity states of the D~2~ receptor in membranes from bovine caudate with a K~low~ of 79 nM. The selectivity r

Antiparkinsonian activity of CY 208–243,

Antiparkinsonian activity of CY 208–243, a partial D-1 dopamine receptor agonist, in MPTP-treated marmosets and patients with Parkinson's disease

✍ J. A. Temlett; N. P. Quinn; P. G. Jenner; C. D. Marsden; E. Pourcher; A.-M. Bonn 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 298 KB

Transdermal dopaminergic D2 receptor ago

Transdermal dopaminergic D2 receptor agonist therapy in Parkinson's disease with N-0923 TDS: A double-blind, placebo-controlled study

✍ J. Thomas Hutton; Leo Verhagen Metman; Thomas N. Chase; Jorge L. Juncos; William 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 35 KB 👁 1 views

## Abstract N‐0923 is a non‐ergot, dopaminergic D~2~ agonist designed to be transdermally available. It has anti‐parkinsonian effects when infused intravenously. An adhesive matrix patch was developed to deliver N‐0923 transdermally (N‐0923 TDS). In this phase II trial, we evaluated the effectiven

Levodopa induces a cytoplasmic localizat

Levodopa induces a cytoplasmic localization of D1 dopamine receptors in striatal neurons in Parkinson's disease

✍ A. Di Rocco; P. Werner 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 113 KB 👁 2 views

Differential interaction of competitive

Differential interaction of competitive NMDA and AMPA antagonists with selective dopamine D-1 and D-2 agonists in a rat model of Parkinson's disease

✍ Peter-Andreas Löschmann; Ullrich Wüllner; Michael T. Heneka; Jörg B. Schulz; Mar 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 179 KB 👁 3 views

1-aminomethyl-5,6-dihydroxy-3-phenylisochroman; NMDA antagonist; CPP; 3-((6)-2-carboxypiperazin-4-yl)-propyl-1-phosphonic acid

Sustained-release (+)-PHNO [MK-458 (HPMC

Sustained-release (+)-PHNO [MK-458 (HPMC)] in the treatment of Parkinson's disease: Evidence for tolerance to a selective D2-receptor agonist administered as a long-acting formulation

✍ Dr. Jesse M. Cedarbaum; Mary Clark; Linda H. Toy; Alison Green-Parsons 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 683 KB

## Abstract 4‐‐Propyl‐9‐hydroxynaphthoxazine, or MK‐458 (HPMC), a selective, nonergot D2 agonist administered orally twice a day in sustained‐release form, was studied as adjunctive therapy with carbidopa‐levodopa (Sinemet) in 12 Parkinson's disease patients with motor response fluctuations. The do